Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

Cardiff Oncology to Participate in Three Upcoming Investor Conferences 
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Sidoti Events, LLC's Year-End Virtual Investor Conference
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.